The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know

被引:43
作者
Doycheva, Iliana [1 ]
Leise, Michael D. [2 ]
Watt, Kymberly D. [2 ]
机构
[1] Med Univ Sofia, Div Gastroenterol & Hepatol, Sofia, Bulgaria
[2] Mayo Clin, Div Gastroenterol & Hepatol, Transplant Ctr, Rochester, MN 55905 USA
关键词
SELECTIVE BOWEL DECONTAMINATION; HUMAN GUT MICROBIOME; BACTERIAL OVERGROWTH; BARRIER FUNCTION; ACUTE REJECTION; CIRRHOTIC RATS; INFECTION; HOMEOSTASIS; PROBIOTICS; IMPACT;
D O I
10.1097/TP.0000000000001008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The intestinal microbiome and immune system are in close symbiotic relationship in health. Gut microbiota plays a role in many chronic liver diseases and cirrhosis. However, alterations in the gut microbiome after liver transplantation and the implications for liver transplant recipients are not well understood and rely mainly on experimental animal studies. Recent advances in molecular techniques have identified that increased intestinal permeability, decreased beneficial bacteria, and increased pathogenic species may play important roles in the early posttransplant period. The associations between microbiota perturbation and postliver transplant infections and acute rejection are evolving. The link with metabolic syndrome, obesity, and cardiac disease in the general population require translation into the transplant recipient. This review focuses on our current knowledge of the known and potential interaction of the microbiome in the liver transplant recipient. Future human studies focused on microbiota changes in liver transplant patients are warranted and expected.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 50 条
  • [41] Retailing in times of soaring inflation: What we know, what we don't know, and a research agenda
    Dekimpe, Marnik G.
    Heerde, Harald J. van
    [J]. JOURNAL OF RETAILING, 2023, 99 (03) : 322 - 336
  • [42] Homeowners Associations as Private Governments: What We Know, What We Don't Know, and Why It Matters
    McCabe, Barbara Coyle
    [J]. PUBLIC ADMINISTRATION REVIEW, 2011, 71 (04) : 535 - 542
  • [43] Time-of-flight in cardiac PET/TC: What do we know and what we should know?
    Matheoud, Roberta
    Lecchi, Michela
    [J]. JOURNAL OF NUCLEAR CARDIOLOGY, 2018, 25 (05) : 1550 - 1553
  • [44] Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections
    Tejeda-Garibay, Susana
    Hoyer, Katrina K.
    [J]. JOURNAL OF FUNGI, 2023, 9 (05)
  • [45] Merkel Cell Carcinoma and Immunosuppression: What We Still Need to Know
    Locke, Frederick L.
    Rollison, Dana E.
    Sondak, Vernon K.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02):
  • [46] Chlamydia pneumoniae and atherosclerosis -: what we know and what we don't
    Ngeh, J
    Anand, V
    Gupta, S
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (01) : 2 - 13
  • [47] Tourist Attribution toward Destination Brands: What Do We Know? What We Do Not Know? Where Should We Be Heading?
    Alamrawy, Mohamed Arfan Taha
    Hassan, Thowayeb H.
    Saleh, Mahmoud I.
    Abdelmoaty, Mostafa A.
    Salem, Amany E.
    Mahmoud, Hassan Marzok Elsayed
    Abdou, Ahmed H.
    Helal, Mohamed Y.
    Abdellmonaem, Amira Hassan
    El-Sisi, Shaymaa Abdul-Wahab
    [J]. SUSTAINABILITY, 2023, 15 (05)
  • [48] Microcredit Under the Microscope: What Have We Learned in the Past Two Decades, and What Do We Need to Know?
    Banerjee, Abhijit Vinayak
    [J]. ANNUAL REVIEW OF ECONOMICS, VOL 5, 2013, 5 : 487 - 519
  • [49] CEO activism. What do we know? What don't we know? A systematic literature review
    Rumstadt, Franz
    Kanbach, Dominik K.
    [J]. SOCIETY AND BUSINESS REVIEW, 2022, 17 (02) : 307 - 330
  • [50] Pathology of catheter-related complications: what we need to know and what should be discovered
    Wang, Lihua
    Jia, Lan
    Jiang, Aili
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2022, 50 (10)